G820V

Category 3/4 — Most DruggableLikely risk alleleLumenal · predictedσ-1 candidateSource card

Glycine → Valine at position 820 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type G820 — hydrogen bond to F704

Fullscreen ↗

DynaMut2 mutant · G820V

Mutant V820 — energy-minimized; local contact network preserved

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost0 gained3 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Hydrogen bond	F704	F704	Preserved
Polar contact	F704	F704	Preserved
Polar contact	R818	R818	Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-1.04kcal/mol

Destabilising — moderate

AlphaMissense

0.927

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationLikely risk allele

Review statuscriteria provided, single submitter

Associated conditionsWolfram syndrome 1

Population frequency (gnomAD v4)Ultra-rare · AF 0.0022%

cDNA changec.2459G>T

ClinVar accessionVCV002442242

Last evaluated1/01/01 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — G820V Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Glycine → Valine at position 820. C-terminal ER-lumenal (calcium binding. ClinVar Likely risk allele, AlphaMissense 0.927, DynaMut2 ΔΔG -1.04 kcal/mol (destabilising).

Identity

Field	Value
Variant	G820V (p.Glycine820Valine)
DNA change	c.2459G>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV002442242
Amino acid change	Glycine (G) → Valine (V)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 820	83.31 — well-folded
Domain	C-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position context	C-terminal lumenal domain · position 820 projects into the ER lumen
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 820 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is small/flexible (glycine — backbone flexibility, no sidechain); the mutant is small hydrophobic (valine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.9267
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-1.04 (Destabilising)
Job ID	178094554342
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178094554342

Clinical Evidence

Field	Value
Classification	Likely risk allele
Review status	criteria provided, single submitter
Last evaluated	1/01/01 00:00
Inheritance	Autosomal recessive Wolfram syndrome 1 phenotype documented.
WFS1 variant landscape	G820V is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

Wolfram syndrome 1

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=1.04 < 2 kcal/mol (fold intact) + AlphaMissense 0.927 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.04 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.927. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
G820V_molstar_viewer.html — interactive 3D viewer (auto-highlights position 820 with ball-and-stick + neighbors within 5Å)
G820V_variant_card.md — this card (source of truth)
G820V_variant_card.html — styled printable card
G820V_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
G820V_wildtype_interactions.pse / G820V_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the G820V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download G820V PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.